Status:
TERMINATED
Efficacy of the ATP Switch Automatic Programming in Implantable Cardioverter Defibrillator (ICD) and Cardiac Resynchronization Therapy Defibrillator (CRT-D) Implanted Patients
Lead Sponsor:
MicroPort CRM
Collaborating Sponsors:
Sorin Group France SAS
Conditions:
Ventricular Arrythmias
Eligibility:
All Genders
18+ years
Brief Summary
Primary objective is to assess the efficacy of the new ATP Autoswitch function in simple, dual or triple chamber ICD.
Detailed Description
The efficacy rate of the ATP Auto-switch function, defined as the % of VT episodes successfully reduced, will be compared with 85%.
Eligibility Criteria
Inclusion
- The patient has been implanted (primo implantation or replacement) with an ICD model PARADYM VR 8250, DR 8550, CRT 8750, CRT 8770 models or any similar or higher range device
- ATP Auto-switch function is programmed ON
Exclusion
- Presence of a contra-indication to the ICD therapy
- Life expectancy less than 12 months
Key Trial Info
Start Date :
November 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2015
Estimated Enrollment :
1254 Patients enrolled
Trial Details
Trial ID
NCT01169246
Start Date
November 1 2009
End Date
February 1 2015
Last Update
March 25 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Brest
Brest, France